Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis : three clinical case studies
Halpern, James Akbar, Faraz Cuell, Alexis Sarapuddin, Ben
Halpern, James
Akbar, Faraz
Cuell, Alexis
Sarapuddin, Ben
Abstract
Tralokinumab is an anti-interleukin-13 monoclonal antibody approved in several geographical regions for the treatment of moderate-to-severe atopic dermatitis. This manuscript presents three case studies of patients with moderate-to-severe atopic dermatitis who had failed on prior treatments and took part in trials of tralokinumab. Data is available for approximately two years in each patient and indicates that treatment with tralokinumab every two weeks was associated with substantial improvements in patient itch, sleep and quality of life, with feedback from the patients suggesting that this had a meaningful impact on their daily lives.
MIDER Authors
Citations
Altmetric:
Date
2023-09
Type
Article
Subject
Dermatology
Collections
Citation
Halpern, J., Akbar, F., Cuell, A., & Sarapuddin, B. (2023). Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis: Three clinical case studies. Dermatological Nursing, 22(3), 35.
Journal / Source Title
Dermatological Nursing
DOI
PMID
Publisher
British Dermatological Nursing Group